View Older Stories View More Recent Stories

Nov 26, 2019 04:06PM Exelixis Announces Webcasts of Investor Conference Presentations in December
Nov 12, 2019 04:05PM Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019
Nov 12, 2019 08:02AM Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma
Nov 8, 2019 05:58AM Exelixis (EXEL) Partner, Daiichi Sankyo, Highlights Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy
Nov 7, 2019 08:01PM Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy
Oct 30, 2019 04:05PM Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 16, 2019 04:05PM Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019
Sep 25, 2019 04:05PM Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
Sep 3, 2019 04:05PM Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019
Jul 31, 2019 04:06PM Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 31, 2019 04:05PM Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer
Jul 17, 2019 04:05PM Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019
Jul 15, 2019 07:03AM Exelixis (EXEL) Reports Updates for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
Jul 15, 2019 07:00AM Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors
May 29, 2019 04:05PM Exelixis Announces Webcasts of Investor Conference Presentations in June 2019
May 16, 2019 08:01AM Exelixis (EXEL), Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
May 16, 2019 08:00AM Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
May 14, 2019 04:05PM Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019
May 13, 2019 06:00AM Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan
May 1, 2019 05:25PM Exelixis (EXEL) Commences Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab
May 1, 2019 04:06PM Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom
May 1, 2019 04:05PM Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update
Apr 25, 2019 06:42AM Exelixis (EXEL) Reports Partner, Takeda Pharmaceutical, to File NDA in Japan for CABOMETYX (Cabozantinib) for Advanced RCC
Apr 25, 2019 06:30AM Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma
Apr 17, 2019 04:05PM Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019
Apr 5, 2019 04:05PM Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019
Mar 5, 2019 04:05PM Exelixis Announces Webcasts of Investor Conference Presentations in March
Feb 12, 2019 04:14PM Exelixis (EXEL) to Initiate Phase 1 Clinical Development of XL092
Feb 12, 2019 04:06PM Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Feb 12, 2019 04:05PM Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts
Feb 7, 2019 04:05PM Exelixis to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 on February 14, 2019
Jan 29, 2019 04:05PM Exelixis to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 12, 2019
Jan 14, 2019 05:38PM Exelixis (EXEL) Announces U.S. FDA Approval of CABOMETYX Tablets for Previously Treated HCC
Jan 14, 2019 05:38PM Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Jan 8, 2019 06:02AM Exelixis (EXEL) Partner Daiichi Sankyo Gratnted Regulatory Approval for MINNEBRO (Esaxerenone) Tablets for Treatment of Hypertension in Japan
Jan 8, 2019 06:00AM Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets for the Treatment of Hypertension in Japan
Dec 5, 2018 01:33AM Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma
Dec 5, 2018 01:30AM Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma
Nov 15, 2018 01:32AM Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
Nov 6, 2018 04:05PM Exelixis to Present at the Stifel 2018 Healthcare Conference on November 13, 2018
Nov 1, 2018 04:05PM Exelixis Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 22, 2018 06:50AM Exelixis (EXEL) Highlights Results from Dose-Escalation Stage of Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab
Oct 22, 2018 06:45AM Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma
Oct 22, 2018 06:17AM Exelixis (EXEL) Highlights Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib
Oct 20, 2018 08:45AM Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcin
Oct 18, 2018 04:05PM Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
Oct 8, 2018 06:05PM Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
Oct 8, 2018 08:05AM Exelixis (EXEL) Reports Initiation of Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib
Oct 8, 2018 08:00AM Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
Sep 25, 2018 04:05PM Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018
View More Recent Stories View Older Stories